HOUSTON ― Intratumoral delivery of an engineered oncolytic virus (DNX-2401) targeting glioblastoma (GBM) cells combined with subsequent immunotherapy was safe and improved survival outcomes in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results